Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The effect of lixisenatide in type 1 diabetes
2013-002259-14Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Dec 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2 trial of lixisenatide in diabetes mellitus type 1 (T1D), sponsored by University of Oxford. Primary endpoint: Meal-time insulin dose reduction required to avoid hypoglycaemia with lixisenatide 10 micrograms/day. Started Dec 2013; status: completed.
02
Drugs
lixisenatide
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2013-002259-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002259-14.